Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Mar. 29, 2019 | Jun. 29, 2018 | |
Document Information [Line Items] | |||
Entity Registrant Name | MILESTONE SCIENTIFIC INC. | ||
Entity Central Index Key | 0000855683 | ||
Trading Symbol | mlss | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Common Stock, Shares Outstanding (in shares) | 40,855,720 | ||
Entity Public Float | $ 15,368,647 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2018 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 743,429 | $ 2,636,956 |
Accounts receivable, net | 1,978,456 | 1,535,513 |
Accounts receivable, related party, net | 100,000 | 1,725,450 |
Note receivable from financing transaction, current | 500,000 | |
Prepaid expenses and other current assets | 414,541 | 436,410 |
Deferred cost, related party | 50,000 | 1,109,671 |
Inventories, net | 1,921,051 | 3,379,209 |
Advances on contracts | 648,783 | 697,192 |
Total current assets | 5,856,260 | 12,020,401 |
Furniture, fixtures and equipment, net | 82,557 | 141,760 |
Patents, net | 435,273 | 2,789,748 |
Note receivable from financing transaction, noncurrent | 650,000 | |
Other assets | 26,878 | 26,878 |
Total assets | 6,400,968 | 15,628,787 |
Current liabilities: | ||
Accounts payable | 1,205,396 | 977,623 |
Accounts payable, related party | 1,663,849 | 985,678 |
Accrued expenses and other payables | 1,481,715 | 2,179,268 |
Accrued expenses, related party | 108,640 | |
Deferred profit, related party | 421,800 | 751,500 |
Deferred revenue, related party | 100,000 | 1,725,450 |
Total current liabilities | 4,872,760 | 6,728,159 |
Deferred gain from financing transaction | 1,400,000 | |
Total liabilities | 4,872,760 | 8,128,159 |
Commitments and contingencies | ||
Stockholders’ equity | ||
Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares issued and outstanding (liquidation preference of $7,000,000 as of December 31, 2018 and 2017) | 7 | 7 |
Common stock, par value $.001; authorized 50,000,000 shares; 33,859,034 shares issued,2,470,565 shares to be issued and 33,825,701 shares outstanding as of December 31, 2018; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017; | 36,330 | 34,593 |
Additional Paid in Capital | 88,414,718 | 86,689,084 |
Accumulated deficit | (85,999,929) | (78,568,284) |
Treasury stock, at cost, 33,333 shares | (911,516) | (911,516) |
Total Milestone Scientific Inc. stockholders' equity | 1,539,610 | 7,243,884 |
Noncontrolling interest | (11,402) | 256,744 |
Total stockholders’ equity | 1,528,208 | 7,500,628 |
Total liabilities and stockholders’ equity | $ 6,400,968 | $ 15,628,787 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Preferred stock, par value (in dollars per share) | $ 0.001 | |
Preferred stock, shares authorized (in shares) | 5,000,000 | |
Preferred stock, shares issued (in shares) | 7,000 | |
Preferred stock, shares outstanding (in shares) | 7,000 | |
Preferred stock, liquidation preference | $ 7,000,000 | |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Common stock, shares issued (in shares) | 33,859,034 | 33,191,571 |
Common stock, shares to be issued (in shares) | 2,470,565 | 1,401,247 |
Common stock, shares outstanding (in shares) | 33,825,701 | 33,158,238 |
Treasury stock, at cost, shares (in shares) | 33,333 | 33,333 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Product sales, net | $ 9,622,076 | $ 11,281,886 |
Cost of products sold | 5,190,775 | 4,312,507 |
Gross profit | 4,431,301 | 6,969,379 |
Selling, general and administrative expenses | 10,645,206 | 11,930,951 |
Research and development expenses | 245,636 | 272,746 |
Impairment of long lived assets | 1,539,794 | |
Total operating expenses | 12,430,636 | 12,203,697 |
Loss from operations | (7,999,335) | (5,234,318) |
Other expenses | (7,232) | (4,930) |
Interest income | 7,447 | 9,298 |
Loss before provision for income taxes and equity in net losses of equity investments | (7,999,120) | (5,229,950) |
Provision for income taxes | (23,986) | (19,093) |
Loss before equity in net earnings (losses) of equity investments | (8,023,106) | (5,249,043) |
(Loss) Earnings on earnings from equity method investment | 329,700 | (120,510) |
(Loss) Earnings on earnings from equity method investment | 329,700 | (120,510) |
Net loss | (7,691,771) | (5,369,553) |
Net loss attributable to noncontrolling interests | (260,126) | (182,760) |
Net loss attributable to Milestone Scientific Inc. | $ (7,431,645) | $ (5,186,793) |
Net loss per share applicable to common stockholders— | ||
Basic (in dollars per share) | $ (0.21) | $ (0.16) |
Diluted (in dollars per share) | $ (0.21) | $ (0.16) |
Weighted average shares outstanding and to be issued— | ||
Basic (in shares) | 35,299,034 | 32,703,897 |
Diluted (in shares) | 35,299,034 | 32,703,897 |
Milestone Education LLC [Member] | ||
(Loss) Earnings on earnings from equity method investment | $ 1,635 | |
(Loss) Earnings on earnings from equity method investment | 1,635 | |
China Joint Venture [Member] | ||
(Loss) Earnings on earnings from equity method investment | 329,700 | (120,510) |
(Loss) Earnings on earnings from equity method investment | $ 329,700 | $ (120,510) |
Consolidated Statement of Chang
Consolidated Statement of Changes in Stockholder Equity - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Treasury Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2016 | 7,000 | 31,727,705 | |||||
Balance at Dec. 31, 2016 | $ 7 | $ 31,720 | $ 82,761,503 | $ (73,381,491) | $ 36,106 | $ (911,516) | $ 8,536,329 |
Stock based compensation | 651,413 | 651,413 | |||||
Common stock to be issued to employee for compensation (in shares) | 10,913 | ||||||
Common stock to be issued to employee for compensation | $ 11 | 14,989 | 15,000 | ||||
Common stock issued to employee for exercise of stock options (in shares) | 83,333 | ||||||
Common stock issued to employee for exercise of stock options | $ 83 | 62,417 | 62,500 | ||||
Common stock issued for payment of consulting services (in shares) | 410,729 | ||||||
Common stock issued for payment of consulting services | $ 419 | 548,092 | 548,511 | ||||
Common stock issued to employee for bonuses (in shares) | 158,082 | ||||||
Common stock issued to employee for bonuses | $ 158 | 259,834 | 259,992 | ||||
Common stock issued for Asset acquisition (in shares) | 1,646,358 | ||||||
Common stock issued for Asset acquisition | $ 1,646 | 2,484,354 | 2,486,000 | ||||
Common Stock exchanged for MMD (in shares) | 311,998 | ||||||
Common Stock exchanged for MMD | $ 312 | (403,710) | 403,398 | ||||
Common stock issued to directors for bonuses (in shares) | 120,000 | ||||||
Common stock issued to directors for bonuses | $ 120 | 159,480 | 159,600 | ||||
Sale of Common Stock - Public Offering (in shares) | 123,700 | ||||||
Sale of Common Stock - Public Offering | $ 124 | 150,712 | 150,836 | ||||
Net loss | (5,186,793) | (182,760) | (5,369,553) | ||||
Balance (in shares) at Dec. 31, 2017 | 7,000 | 34,592,818 | |||||
Balance at Dec. 31, 2017 | $ 7 | $ 34,593 | 86,689,084 | (78,568,284) | 256,744 | (911,516) | 7,500,628 |
Stock based compensation | 409,021 | 409,021 | |||||
Common stock to be issued to employee for compensation (in shares) | 47,402 | ||||||
Common stock to be issued to employee for compensation | $ 47 | 44,953 | 45,000 | ||||
Common stock issued for payment of consulting services (in shares) | 350,102 | ||||||
Common stock issued for payment of consulting services | $ 350 | 289,400 | 289,750 | ||||
Common stock issued to employee for bonuses (in shares) | 25,000 | ||||||
Common stock issued to employee for bonuses | $ 25 | 29,475 | $ 29,500 | ||||
Common stock issued for Asset acquisition (in shares) | 244,959 | 244,959 | |||||
Common stock issued for Asset acquisition | $ 245 | 286,357 | $ 286,601 | ||||
Net loss | (7,431,645) | (260,126) | (7,691,771) | ||||
Common stock to be issued to employee for bonuses (in shares) | 511,155 | ||||||
Common stock to be issued to employee for bonuses | $ 511 | 449,488 | 449,999 | ||||
Common stock to be issued for payment of consulting services (in shares) | 535,437 | ||||||
Common stock to be issued for payment of consulting services | $ 536 | 209,463 | 209,999 | ||||
Common stock to be issued to employee for compensation (in shares) | 22,727 | ||||||
Common stock to be issued to employee for compensation | $ 23 | 7,477 | 7,500 | ||||
Acquired controlling interest in Milestone Education | (8,020) | (8,020) | |||||
Balance (in shares) at Dec. 31, 2018 | 7,000 | 36,329,600 | |||||
Balance at Dec. 31, 2018 | $ 7 | $ 36,330 | $ 88,414,718 | $ (85,999,929) | $ (11,402) | $ (911,516) | $ 1,528,208 |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Cash flows from operating activities: | ||
Net loss | $ (7,691,771) | $ (5,369,553) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation expense | 66,604 | 62,474 |
Amortization of patents | 814,681 | 510,676 |
Impairment of long lived assets | 1,539,794 | |
Stock compensation | 409,021 | 651,413 |
(Income) loss on China joint venture | (329,700) | 120,510 |
Increase inventory allowance | 543,545 | 219,834 |
Increase in deferred cost reserve | 1,250,928 | |
Changes in operating assets and liabilities: | ||
Increase in accounts receivable | (442,943) | (733,129) |
Decrease (increase) in accounts receivable, related party | (192,540) | 989,150 |
Decrease in other receivables | 10,000 | |
Decrease in inventories | 914,613 | 1,003,676 |
Decrease in advances on contracts | 48,409 | 3,708 |
Decrease (increase) in prepaid expenses and other current assets | 21,869 | (144,481) |
Decrease in other assets | (9,523) | |
Increase (decrease) in accounts payable | 227,773 | (363,584) |
Increase (decrease) in accounts payable, related party | 678,171 | (249,374) |
Increase in deferred cost, related party | (191,257) | (489,630) |
Increase in accrued expenses | 620,797 | 1,834,749 |
Decrease in accrued expenses, related party | (108,640) | |
Increase in deferred revenue, related party | 192,540 | 723,650 |
Net cash used in operating activities | (1,628,106) | (1,229,434) |
Cash flows from investing activities: | ||
Purchase of intangible assets | (39,520) | |
Purchase of property and equipment | (7,401) | (6,008) |
Acquisition of Milestone Education | (8,020) | |
Purchase of intangibles assets-Apad | (153,647) | |
Net cash used in investing activities | (15,421) | (199,175) |
Cash flows from financing activities: | ||
(Payments) proceeds financing transaction | (250,000) | 250,000 |
Proceeds from exercise of stock options | 62,500 | |
Net proceeds on Public Placement Offering | 150,836 | |
Net cash (used in) provided by financing activities | (250,000) | 463,336 |
Net decrease in cash and cash equivalents | (1,893,527) | (965,273) |
Cash and cash equivalents at beginning of period | 2,636,956 | 3,602,229 |
Cash and cash equivalents at end of period | 743,429 | 2,636,956 |
Supplemental disclosure of cash flow information: | ||
Shares issued to employees for compensation | 45,000 | 194,885 |
Shares issued to consultants in lieu of cash payments | 289,750 | 350,249 |
Deferred revenue and accounts receivable, related party adjustment | 1,817,990 | 10,000 |
Shares issued for assets acquired | 2,486,000 | |
(Reversal) sale of Milestone China share, financing transaction | $ (1,400,000) | $ 1,150,000 |
Note A - Organization and Busin
Note A - Organization and Business | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE A — ORGANIZATION AND BUSINESS All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia System®; and The Wand ®. Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand® CompuDent®, STA Single Tooth Anesthesia System® CompuMed®. CompuDent® CompuMed® 60 five 5 June 2017, 510 CompuFlo During 2016, 510 June 2017, CompuFlo In December 2016, 510 not 510 510 2019. In November 20, 2018, not 1003 December 20, 2018, 1003 May 20, 2020. On January 24, 2019, not 1003 |
Note B - Going Concern and Liqu
Note B - Going Concern and Liquidity | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | NOTE B- GOING CONCERN AND LIQUIDITY In accordance with Accounting Standard Codification (“ASC”) 205 40, one December 31, 2018, $.7 $1.0 $2.6 $5.3 2017, February 2019 not 12 Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever. Management is actively pursuing financing or other strategic plans but can provide no In February 2019, $2.0 5,715,000 1,428,000 $198,000 567,400 Also, in February 2019, $250,000 714,286 178,594 Bp4 Bp4’s These consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not may |
Note C - Summary of Significant
Note C - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | NOTE C — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned) and Milestone Medical (majority owned). Milestone Education was a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. During 2018, 50% September 2018, 100%. 2. Certain reclassifications have been made to the 2017 2018 no 3. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates . 4. Under ASC 606, 606, five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns We do not not not Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Rev We operate in two 31, 2018 2017. 5. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Because Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE Milestone Scientific does not not not 810. not 6. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three 7. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not December 31, 2018 2017, $10,000. 8. Milestone Scientific generally does not not 9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first December 31, 2018 2017, $763,000 $220,000, 10. Investments in which Milestone Scientific can exercise significant influence, but do not may 11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven 12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost. Patent defense costs, to the extent applicable, are expensed as incurred. 13. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not • significant under performance relative to expected historical or projected future operating results, • significant changes in the manner of our use of the acquired assets or the strategy for our overall business • significant negative industry or economic trends • significant technological changes, which would render the technology obsolete Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. See Note J. 14. Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, no 15. Research and development costs, which consist principally of new product development costs payable to third 16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. At December 31, 2018 2017, no No 2015, 2016, 2017 17. Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two two two not not The Company did not two not not Since Milestone Scientific had net losses for 2018 2017, not 3,203,553 3,710,335 December 31, 2018 2017, 18. Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may 19. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model. See note L. 20. In February 2016, No.2016 02, 842 December 15, 2018. not In June 2016, No.2016 13, 326 December 15, 2018. Milestone Scientific will adopt this standard in 2019, July 2017, No.2017 11, 260 480 815 December 15, 2018. December 2018, |
Note D - Notes Receivable
Note D - Notes Receivable | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Financing Receivables [Text Block] | NOTE D — NOTES RECEIVABLE In June 2017, forty 40% 10 $1,400,000 $125,000 $1,275,000 The note was payable in quarterly installments of $125,000 10 $1,400,000 first two 10 $1,400,000. forty 40% As of March 2, 2018, April 2018, $250,000 $1,150,000 $1,400,000. No |
Note E - Inventories
Note E - Inventories | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | NOTE E — INVENTORIES Inventories consist of the following: December 31, 2018 December 31, 2017 Dental finished goods, net $ 1,609,000 $ 2,846,272 Medical finished goods, net 188,133 475,285 Component parts and other materials 123,918 57,652 Total inventories $ 1,921,051 $ 3,379,209 At December 31, 2018, $454,183 $309,196 December 31 ,2017 $220,000 |
Note F - Advances on Contracts
Note F - Advances on Contracts | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Advances to Contract Manufacturer [Text Block] | NOTE F — ADVANCES ON CONTRACTS The advances on contracts represent funding of future STA inventory purchases and epidural replacements parts. The balance of the advances as of December 31, 2018 2017 $649,000 $697,000 |
Note G - Consolidation of Varia
Note G - Consolidation of Variable Interest Entity | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Variable Interest Entity Disclosure [Text Block] | NOTE G – CONSOLIDATION OF VARIABLE INTEREST ENTITY Milestone Education was a 50% 2013 84% December 31, 2018 2017. 50% September 2018 $8,020. |
Note H - Investment in and Tran
Note H - Investment in and Transactions with Unconsolidated Subsidiaries | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | NOTE H – INVESTMENT IN AND TRANSACTIONS WITH UNCONSOLIDATED SUBSIDIARIES Milestone China Ltd. Ownership In June 2014, $1 772 40% In June 2017, forty 40% 10 $1,400,000 $125,000 $1,275,000 $125,000 10 $1,400,000 first two 10 $1,400,000 December 31, 2017. forty 40% As of March 2, 2018, April 2018, $250,000 $1,150,000 $1,400,000. No Related Party Transactions Milestone China is Milestone Scientific’s exclusive distributor in China. During 2017 2018 2018, $900,000 $2,071,000 twelve December 31, 2017. As of December 31, 2018, $0.1 $0.5 December 31, 2017, 1.7 $1.1 During 2018 2.8 $200,000 July 2018 November 2018 $1,425,000 December 2018. 2018 $900,000 $1.25 Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323 40% third At December 31, 2018 2017, $421,800 $751,500, twelve December 31, 2018 2017, $329,700 $120,510, third Equity Method Disclosures As of December 31, 2018, December 31, 2017, $0. December 31, 2018, December 31, 2017, $3,380,388 $3,147,470, The following table includes summarized financial information (unaudited) of Milestone China: December 31, 2018 December 31, 2017 Assets: (unaudited) (unaudited) Current assets $ 10,587,648 $ 13,127,422 Non-current assets 4,603,485 3,213,520 Total assets: $ 15,191,133 $ 16,340,942 Liabilities: Current liabilities 17,696,033 18,468,937 Stockholders' deficit (2,504,900 ) (2,127,995 ) Total liabilities and stockholders’ deficit $ 15,191,133 $ 16,340,942 December 31, 2018 December 31, 2017 (unaudited) (unaudited) Net sales $ 7,598,998 $ 1,394,760 Cost of goods sold 3,539,138 477,200 Gross profit 4,059,860 917,560 Other expenses (4,642,154 ) (5,975,360 ) Net Losses $ (582,294 ) $ (5,057,800 ) |
Note I - Furniture, Fixtures an
Note I - Furniture, Fixtures and Equipment | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE I— FURNITURE, FIXTURES AND EQUIPMENT 2018 2017 Furniture, Fixtures and Equipment consist of the Leasehold improvements $ 24,734 $ 24,734 Office furniture and equipment 134,948 134,947 Molds 7,200 7,200 Trade show displays 143,357 143,357 Computers and software 278,766 270,904 Tooling Safety Wand 125,022 125,022 Tooling equipment-STA & Wand 11,100 11,100 EPI and IA Instruments 82,362 82,363 STA Trials Instruments 63,752 63,752 Total 871,241 863,379 Less accumulated depreciation (788,684 ) (721,619 ) Total $ 82,557 $ 141,760 Depreciation expense was $66,604 $62,474 December 31, 2018 2017, |
Note J - Patents
Note J - Patents | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | NOTE J — PATENTS December 31, 2018 December 31, 2017 Cost Impairment Accumulated Amortization Net Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (942,590 ) $ 435,273 $ 1,377,863 $ - $ (787,821 ) $ 590,042 Epidural-Apad acquired patents 2,639,647 (1,539,794 ) (1,099,853 ) - 2,639,647 - (439,941 ) 2,199,706 Total $ 4,017,510 $ (1,539,794 ) $ (2,042,443 ) $ 435,273 $ 4,017,510 $ - $ (1,227,762 ) $ 2,789,748 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 20 $814,681 $510,676 December 31, 2018 2017, 2019 2023 $53,000, $53,000, $53,000, $47,000 $33,000. On July 13, 2017, 1,646,358 $2,486,000 not twenty-five 250,000 2018 244,959 $286,601. $2,639,000 three During 2018, 2017 not $1.5 |
Note K - Stockholders' Equity
Note K - Stockholders' Equity | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE K — STOCKHOLDERS’ EQUITY ISSUANCE COMMON STOCK In December 2016, 2,000,000 1,592,775 92,775 0.75 .75 $1.50 $3,000,000. three $2.55 January 2017, 123,700 $1.499 $186,000. PREFERRED STOCK In May 2014, $10 $3 two million $1.50 $7 7,000 $1,000 $2.545, May 14, 2019. May 14, 2019, $2.545 $1.50 not $3.15 SHARES TO BE ISSUED As of December 31, 2018, 2017, 1,908,813 1,374,931 December 31, 2018, 2017, 561,752 26,316 2019 SHARES RESERVED FOR FUTURE ISSUANCE At December 31, 2018 2017, 5,315,974 5,111,582 2,845,409 3,710,335 |
Note L - Stock Option Plans
Note L - Stock Option Plans | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | NOTE L — STOCK OPTION PLANS The 2004 750,000 may not three five no December 31, 2018 2017 In June 2011, 2011 "2011 2,000,000 2016 4,000,000. three five Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the twelve December 31, 2018 2017, $398,301 $636,058 December 31, 2018 2017, $263,974 $603,979 1.75 3.04 December 31, 2018 2017, A summary of option activity for employees under the plans and changes during the years ended December 31, 2018 2017 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding December 31, 2016 1,511,995 1.74 2.97 102,605 Granted 1,806,741 1.82 4.69 25,610 Exercised during 2017 (83,333 ) 0.75 - - Forfeited or expired (1,250,068 ) - - - Options outstanding December 31, 2017 1,985,335 1.74 3.04 25,160 Exercisable, December 31, 2017 1,317,441 1.84 2.46 8,537 Granted - - - - Exercised during 2018 - - - - Forfeited or expired (315,114 ) 1.50 - - Options outstanding December 31, 2018 1,670,221 1.71 2.40 - Exercisable, December 31, 2018 1,317,632 1.79 2.15 - The weighted-average fair value of the options granted during 2018 2017 $0 $1.73 2018 2017 2018 2017 Volatility - 81.23%-97.24% Risk-free interest - 1.4%-2.2% Expected Life - 2-5 years Dividend yield - 0 % Forfeiture Rate - 6 % A summary of option activity for non-employees under the plans and changes during the years ended December 31, 2018 2017, Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding December 31, 2016 224,999 2.53 5.32 - Granted - - - - Exercised during 2017 - - - - Forfeited or expired - - - - Options outstanding December 31, 2017 224,999 2.53 4.32 - Exercisable, December 31, 2017 23,067 2.22 4.38 - Granted 8,333 0.75 4.33 Exercised during 2018 - - - - Forfeited or expired (200,000 ) 2.55 - - Options outstanding December 31, 2018 33,332 1.87 2.94 - Exercisable, December 31, 2018 27,777 2.10 2.66 - The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the twelve December 31, 2018 2017, $10,720 $9,384 |
Note M - Employment Contract an
Note M - Employment Contract and Consulting Agreements | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Employment and Consulting Agreements [Text Block] | NOTE M–EMPLOYMENT CONTRACT AND CONSULTING AGREEMENTS Employment Contracts As of September 1, 2009, five "2009 2009 one August 1 not 2009 $300,000 may $400,000, one one five 110% 10% one third 3 one third 30 $4,900 $7,200, $203,111. In accordance with the 2009 1,055,135 $1,205,707 December 31, 2018 886,866 $1,030,875 December 31, 2017 On December 1, 2016, $280,000 one September 1, 2016 August 31, 2017 ( one September 1 st August 31 st June 1st not In July 2017, three $300,000 may $400,000, one one five second third In July 2017, 921,942 $2.00 five second third On October 2, 2017, $300,000 one one $30,000 $1,200 July 10, 2017. In February 2018, October 2, 2017, $175,000, December 31, 2018. In July 2017, ten $300,000 $100,000 $200,000 first fifteen 15 one 280G 4 In July 2017, ten $100,000 On October 5, 2017, October 2, 2017, July 2017 On October 5, 2017, $200,000 one 100,000 December 19 ,2017 25,000 100,000 On December 19, 2017 2017 not no |
Note N - Income Taxes
Note N - Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE N — INCOME TAXES Due to Milestone Scientific's history of operating losses, a full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets At December 31, 2018 2017, no Deferred tax attributes resulting from differences between financial accounting amounts and tax bases of assets and liabilities at December 31, 2018 2017 2018 2017 Allowance for doubtful accounts $ 3,000 $ 3,000 Warranty reserve 29,000 20,000 Impaired Assets 435,000 5,000 Inventory Reserve 551,000 Capital Gains - 45,000 Deferred officers' compensation 715,000 636,000 Depreciation and Amortization 345,000 181,000 Deferred revenue 478,000 Net operating loss carryforward 16,500,000 15,116,000 Subtotal 18,578,000 16,484,000 Valuation allowance (18,578,000 ) (16,484,000 ) Non-current deferred tax asset $ - $ - The deferred tax asset, before valuation allowance, has been calculated on rates anticipated to be effect when the temporary differences reverse. Accordingly, based on the change in Federal tax rates promulgated in December 2017, January 1, 2018, 21% December 22, 2017, $8,677,000, As of December 31, 2018, $65,300,000. December 31, 2017, $60,000,000, December 2038. December 31, 2018, $30,800,000. December 31, 2017 $26,000,000. December 2038. The utilization of Milestone Scientific's net operating losses may 382 may 100% As of December 31, 2018, 2017, $24,000 $19,000 Accounting for uncertainties in income taxes prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. At December 31, 2018 2017, no No 2015, 2016, 2017 A reconciliation of the statutory tax rates for the years ended December 31, 2018 2017 Statutory rate 21 % 34 % State income tax-all states 7 % 6 % Non-deductible Stock based compensation 0 % 0 % Deferred provision for effect of change in Federal rate 0 % 164 % 28 % 204 % Valuation allowance -28 % -204 % Effective tax rate 0 % 0 % |
Note O - Segment and Geographic
Note O - Segment and Geographic Data | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Product Sales and Significant Customers and Vendors Disclosure [Text Block] | NOTE O — SEGMENT AND GEOGRAPHIC DATA We conduct our business through two Years Ended December 31, Sales Net Sales: 2018 2017 Dental $ 9,502,276 $ 11,279,886 Medical 119,800 2,000 Total net sales $ 9,622,076 $ 11,281,886 Operating Income (Loss): 2018 2017 Dental $ 1,373,178 $ 3,127,570 Medical (2,611,231 ) (2,389,145 ) Corporate (6,761,282 ) (5,972,743 ) Total operating loss $ (7,999,335 ) $ (5,234,318 ) Depreciation and Amortization: 2018 2017 Dental $ 16,474 $ 17,305 Medical 24,492 26,950 Corporate 840,319 528,895 Total depreciation and amortization $ 881,285 $ 573,150 Income (loss) before taxes and equity in earnings of affiliates: 2018 2017 Dental $ 1,363,662 $ 3,136,167 Medical (2,704,630 ) (2,391,082 ) Corporate (6,658,152 ) (5,975,035 ) Total loss before taxes and equity in earnings of affiliate $ (7,999,120 ) $ (5,229,950 ) The following table presents information about our operations by geographic area as December 31, 2018 2017. 2018 Dental Medical Total Domestic US / Canada: Device $ 491,375 $ 32,500 $ 523,875 Handpieces 4,211,243 - 4,211,243 Other 96,088 - 96,088 Total Domestic US / Canada $ 4,798,706 $ 32,500 $ 4,831,206 International Rest of the World: Device $ 1,292,844 $ 81,000 $ 1,373,844 Handpieces 2,444,639 6,100 2,450,739 Other 66,087 200 66,287 Total International Rest of the World $ 3,803,570 $ 87,300 $ 3,890,870 International China: Device $ 109,374 $ - $ 109,374 Handpieces 790,626 - 790,626 Other - - - Total International China $ 900,000 $ - $ 900,000 Total Product Sales $ 9,502,276 $ 119,800 $ 9,622,076 The following table presents information about our operations by geographic area as December 31, 2018 2017. 2017 Dental Medical Total Domestic US / Canada: Device $ 914,495 $ - $ 914,495 Handpieces 4,346,664 - 4,346,664 Other 78,550 - 78,550 Total Domestic US / Canada $ 5,339,709 $ - $ 5,339,709 International Rest of the World: Device $ 1,427,016 $ - $ 1,427,016 Handpieces 2,325,622 2,000 2,327,622 Other 116,539 - 116,539 Total International Rest of the World $ 3,869,177 $ 2,000 $ 3,871,177 International China: Device $ 643,600 $ - $ 643,600 Handpieces 1,425,600 - 1,425,600 Other 1,800 - 1,800 Total International China $ 2,071,000 $ - $ 2,071,000 Total Product Sales $ 11,279,886 $ 2,000 $ 11,281,886 Total Assets: December 31, 2018 December 31, 2017 Dental $ 5,169,944 $ 10,255,144 Medical 328,208 655,513 Corporate 902,816 4,718,130 Total assets $ 6,400,968 $ 15,628,787 |
Note P - Concentration
Note P - Concentration | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | NOTE P -- CONCENTRATIONS Milestone Scientific has informal arrangements with third CompuDent CompuMed December 31, 2018 2017. For the twelve December 31, 2018, 53% two one 43% 10% twelve December 31, 2017, 70% two one 51% 19% Accounts receivable for the major customer/distributors amounted to approximately or 82%, 49% 33% December 31, 2018. one $2,555,000, 78% December 31, 2017. December 31, 2018, $1,917,990 $1,817,990 December 31, 2018. $1,250,928 |
Note Q - Related Party Transact
Note Q - Related Party Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE Q -- RELATED PARTY TRANSACTIONS United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were $1.2 $2.1 December 31, 2018 2017, December 31, 2018 2017, $1.3 $1.0 February 2019, 285,714 $.35 $100,000 December 31, 2018. During 2018 December 31, 2018, $342,540 Also, during the year ended December 31, 2018, 1,000 June 2018, December 31, 2018, $750,000 $686,365, 2.8 $200,000 July 2018 November 2018 $1,425,000 December 2018. 2018 $900,000 $1.25 Milestone China In June 2014, $1 772 40% Other In August 2016, three $100,000 31, 2018 2017, In January 2017, twelve twelve $80,000 31, 2018 2017, The Director of Clinical Affairs’ royalty fee was approximately $465,000 $554,000 December 31, 2018 2017, $186,000 $275,000 December 31, 2018, 2017, December 31, 2018, 2017 $364,000 $162,000, |
Note R - Commitments and Other
Note R - Commitments and Other | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE R — COMMITMENTS ( 1 Milestone Scientific has informal arrangements with third January 2018, 2,000 third 2018, $873,400 December 31, 2018, $596,724 December 31, 2018 $259,801 $649,000 $697,000 December 31, 2018 2017, ( 2 The technology underlying the Safety Wand® and CompuFlo CompuDent January 1, 2005. 2.5% 5% third The Director of Clinical Affairs’ royalty fee was approximately $465,000 $554,000 December 31, 2018 2017, $186,000 $275,000 December 31, 2018 2017, December 31, 2018 2017 $364,000 $162,000, The headquarters for Milestone Scientific is located at 220 7,625 January 31, 2020 $12,522. |
Note S - Pension Plan
Note S - Pension Plan | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | NOTE S — PENSION PLAN Milestone Scientific has a Defined Contribution Plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone Scientific does not not |
Note T - Subsequent Events
Note T - Subsequent Events | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE T — SUBSEQUENT EVENTS In February 2019, $2.0 5,715,000 1,428,000 5 $.50. $198,000 567,400 Also, in February 2019, $250,000 714,286 178,594 Bp4 Bp4’s F- 25 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | 1. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned) and Milestone Medical (majority owned). Milestone Education was a variable interest entity of which Milestone Scientific is the primary beneficiary and is consolidated into Milestone Scientific's financial statements. During 2018, 50% September 2018, 100%. |
Reclassification, Policy [Policy Text Block] | 2. Certain reclassifications have been made to the 2017 2018 no |
Use of Estimates, Policy [Policy Text Block] | 3. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates . |
Revenue Recognition, Policy [Policy Text Block] | 4. Under ASC 606, 606, five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns We do not not not Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Rev We operate in two 31, 2018 2017. |
Consolidation, Variable Interest Entity, Policy [Policy Text Block] | 5. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Because Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE Milestone Scientific does not not not 810. not |
Cash and Cash Equivalents, Policy [Policy Text Block] | 6. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three |
Trade and Other Accounts Receivable, Policy [Policy Text Block] | 7. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not December 31, 2018 2017, $10,000 |
Standard Product Warranty, Policy [Policy Text Block] | 8. Milestone Scientific generally does not not |
Inventory, Policy [Policy Text Block] | 9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first December 31, 2018 2017, $763,000 $220,000, |
Equity Method Investments [Policy Text Block] | 10. Investments in which Milestone Scientific can exercise significant influence, but do not may |
Property, Plant and Equipment, Policy [Policy Text Block] | 11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | 12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized at the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost. Patent defense costs, to the extent applicable, are expensed as incurred. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | 13. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not • significant under performance relative to expected historical or projected future operating results, • significant changes in the manner of our use of the acquired assets or the strategy for our overall business • significant negative industry or economic trends • significant technological changes, which would render the technology obsolete Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. See Note J. |
Cost of Goods and Services Sold, Shipping and Handling, Policy [Policy Text Block] | 14. Milestone Scientific includes shipping and handling costs, if any, in cost of goods sold. These costs are paid by or billed to customers at the time of shipments. Domestic and international shipments are FOB warehouse; therefore, no |
Research and Development Expense, Policy [Policy Text Block] | 15. Research and development costs, which consist principally of new product development costs payable to third |
Income Tax, Policy [Policy Text Block] | 16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. At December 31, 2018 2017, no No 2015, 2016, 2017 |
Earnings Per Share, Policy [Policy Text Block] | 17. Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two two two not not The Company did not two not not Since Milestone Scientific had net losses for 2018 2017, not 3,203,553 3,710,335 December 31, 2018 2017, |
Fair Value of Financial Instruments, Policy [Policy Text Block] | 18. Fair Value Measurements: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | 19. Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model. See note L. |
New Accounting Pronouncements, Policy [Policy Text Block] | 20. In February 2016, No.2016 02, 842 December 15, 2018. not In June 2016, No.2016 13, 326 December 15, 2018. Milestone Scientific will adopt this standard in 2019, July 2017, No.2017 11, 260 480 815 December 15, 2018. December 2018, |
Note E - Inventories (Tables)
Note E - Inventories (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | Inventories consist of the following: December 31, 2018 December 31, 2017 Dental finished goods, net $ 1,609,000 $ 2,846,272 Medical finished goods, net 188,133 475,285 Component parts and other materials 123,918 57,652 Total inventories $ 1,921,051 $ 3,379,209 |
Note H - Investment in and Tr_2
Note H - Investment in and Transactions with Unconsolidated Subsidiaries (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Equity Method Investments [Table Text Block] | December 31, 2018 December 31, 2017 Assets: (unaudited) (unaudited) Current assets $ 10,587,648 $ 13,127,422 Non-current assets 4,603,485 3,213,520 Total assets: $ 15,191,133 $ 16,340,942 Liabilities: Current liabilities 17,696,033 18,468,937 Stockholders' deficit (2,504,900 ) (2,127,995 ) Total liabilities and stockholders’ deficit $ 15,191,133 $ 16,340,942 December 31, 2018 December 31, 2017 (unaudited) (unaudited) Net sales $ 7,598,998 $ 1,394,760 Cost of goods sold 3,539,138 477,200 Gross profit 4,059,860 917,560 Other expenses (4,642,154 ) (5,975,360 ) Net Losses $ (582,294 ) $ (5,057,800 ) |
Note I - Furniture, Fixtures _2
Note I - Furniture, Fixtures and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | 2018 2017 Furniture, Fixtures and Equipment consist of the Leasehold improvements $ 24,734 $ 24,734 Office furniture and equipment 134,948 134,947 Molds 7,200 7,200 Trade show displays 143,357 143,357 Computers and software 278,766 270,904 Tooling Safety Wand 125,022 125,022 Tooling equipment-STA & Wand 11,100 11,100 EPI and IA Instruments 82,362 82,363 STA Trials Instruments 63,752 63,752 Total 871,241 863,379 Less accumulated depreciation (788,684 ) (721,619 ) Total $ 82,557 $ 141,760 |
Note J - Patents (Tables)
Note J - Patents (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | December 31, 2018 December 31, 2017 Cost Impairment Accumulated Amortization Net Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (942,590 ) $ 435,273 $ 1,377,863 $ - $ (787,821 ) $ 590,042 Epidural-Apad acquired patents 2,639,647 (1,539,794 ) (1,099,853 ) - 2,639,647 - (439,941 ) 2,199,706 Total $ 4,017,510 $ (1,539,794 ) $ (2,042,443 ) $ 435,273 $ 4,017,510 $ - $ (1,227,762 ) $ 2,789,748 |
Note L - Stock Option Plans (Ta
Note L - Stock Option Plans (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding December 31, 2016 1,511,995 1.74 2.97 102,605 Granted 1,806,741 1.82 4.69 25,610 Exercised during 2017 (83,333 ) 0.75 - - Forfeited or expired (1,250,068 ) - - - Options outstanding December 31, 2017 1,985,335 1.74 3.04 25,160 Exercisable, December 31, 2017 1,317,441 1.84 2.46 8,537 Granted - - - - Exercised during 2018 - - - - Forfeited or expired (315,114 ) 1.50 - - Options outstanding December 31, 2018 1,670,221 1.71 2.40 - Exercisable, December 31, 2018 1,317,632 1.79 2.15 - Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding December 31, 2016 224,999 2.53 5.32 - Granted - - - - Exercised during 2017 - - - - Forfeited or expired - - - - Options outstanding December 31, 2017 224,999 2.53 4.32 - Exercisable, December 31, 2017 23,067 2.22 4.38 - Granted 8,333 0.75 4.33 Exercised during 2018 - - - - Forfeited or expired (200,000 ) 2.55 - - Options outstanding December 31, 2018 33,332 1.87 2.94 - Exercisable, December 31, 2018 27,777 2.10 2.66 - |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2018 2017 Volatility - 81.23%-97.24% Risk-free interest - 1.4%-2.2% Expected Life - 2-5 years Dividend yield - 0 % Forfeiture Rate - 6 % |
Note N - Income Taxes (Tables)
Note N - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2018 2017 Allowance for doubtful accounts $ 3,000 $ 3,000 Warranty reserve 29,000 20,000 Impaired Assets 435,000 5,000 Inventory Reserve 551,000 Capital Gains - 45,000 Deferred officers' compensation 715,000 636,000 Depreciation and Amortization 345,000 181,000 Deferred revenue 478,000 Net operating loss carryforward 16,500,000 15,116,000 Subtotal 18,578,000 16,484,000 Valuation allowance (18,578,000 ) (16,484,000 ) Non-current deferred tax asset $ - $ - |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2018 2017 Statutory rate 21 % 34 % State income tax-all states 7 % 6 % Non-deductible Stock based compensation 0 % 0 % Deferred provision for effect of change in Federal rate 0 % 164 % 28 % 204 % Valuation allowance -28 % -204 % Effective tax rate 0 % 0 % |
Note O - Segment and Geograph_2
Note O - Segment and Geographic Data (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Years Ended December 31, Sales Net Sales: 2018 2017 Dental $ 9,502,276 $ 11,279,886 Medical 119,800 2,000 Total net sales $ 9,622,076 $ 11,281,886 Operating Income (Loss): 2018 2017 Dental $ 1,373,178 $ 3,127,570 Medical (2,611,231 ) (2,389,145 ) Corporate (6,761,282 ) (5,972,743 ) Total operating loss $ (7,999,335 ) $ (5,234,318 ) Depreciation and Amortization: 2018 2017 Dental $ 16,474 $ 17,305 Medical 24,492 26,950 Corporate 840,319 528,895 Total depreciation and amortization $ 881,285 $ 573,150 Income (loss) before taxes and equity in earnings of affiliates: 2018 2017 Dental $ 1,363,662 $ 3,136,167 Medical (2,704,630 ) (2,391,082 ) Corporate (6,658,152 ) (5,975,035 ) Total loss before taxes and equity in earnings of affiliate $ (7,999,120 ) $ (5,229,950 ) Total Assets: December 31, 2018 December 31, 2017 Dental $ 5,169,944 $ 10,255,144 Medical 328,208 655,513 Corporate 902,816 4,718,130 Total assets $ 6,400,968 $ 15,628,787 |
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] | 2018 Dental Medical Total Domestic US / Canada: Device $ 491,375 $ 32,500 $ 523,875 Handpieces 4,211,243 - 4,211,243 Other 96,088 - 96,088 Total Domestic US / Canada $ 4,798,706 $ 32,500 $ 4,831,206 International Rest of the World: Device $ 1,292,844 $ 81,000 $ 1,373,844 Handpieces 2,444,639 6,100 2,450,739 Other 66,087 200 66,287 Total International Rest of the World $ 3,803,570 $ 87,300 $ 3,890,870 International China: Device $ 109,374 $ - $ 109,374 Handpieces 790,626 - 790,626 Other - - - Total International China $ 900,000 $ - $ 900,000 Total Product Sales $ 9,502,276 $ 119,800 $ 9,622,076 2017 Dental Medical Total Domestic US / Canada: Device $ 914,495 $ - $ 914,495 Handpieces 4,346,664 - 4,346,664 Other 78,550 - 78,550 Total Domestic US / Canada $ 5,339,709 $ - $ 5,339,709 International Rest of the World: Device $ 1,427,016 $ - $ 1,427,016 Handpieces 2,325,622 2,000 2,327,622 Other 116,539 - 116,539 Total International Rest of the World $ 3,869,177 $ 2,000 $ 3,871,177 International China: Device $ 643,600 $ - $ 643,600 Handpieces 1,425,600 - 1,425,600 Other 1,800 - 1,800 Total International China $ 2,071,000 $ - $ 2,071,000 Total Product Sales $ 11,279,886 $ 2,000 $ 11,281,886 |
Note A - Organization and Bus_2
Note A - Organization and Business (Details Textual) | Dec. 31, 2018 |
Number of Countries in which Entity Operates | 60 |
Note B - Going Concern and Li_2
Note B - Going Concern and Liquidity (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | ||||
Mar. 31, 2019 | Feb. 28, 2019 | May 31, 2014 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 743,429 | $ 2,636,956 | $ 3,602,229 | |||
Net Current Assets | 1,000,000 | 5,300,000 | ||||
Proceeds from Stock Options Exercised | 62,500 | |||||
Proceeds from Issuance of Private Placement | $ 250,000 | $ 10,000,000 | $ 150,836 | |||
Private Placement [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 2,000,000 | |||||
Subsequent Event [Member] | Warrants, Public Offering [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,428,000 | |||||
Subsequent Event [Member] | Warrants, Private Offering [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 178,594 | |||||
Subsequent Event [Member] | Public Offering [Member] | ||||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,000,000 | |||||
Stock Issued During Period, Shares, New Issues | 5,715,000 | |||||
Proceeds from Stock Options Exercised | $ 198,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 567,400 | |||||
Subsequent Event [Member] | Private Placement [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 714,286 |
Note C - Summary of Significa_2
Note C - Summary of Significant Accounting Policies (Details Textual) | 1 Months Ended | 12 Months Ended | |
Sep. 30, 2018 | Dec. 31, 2018USD ($)shares | Dec. 31, 2017USD ($)shares | |
Number of Operating Segments | 2 | ||
Allowance for Doubtful Accounts Receivable, Ending Balance | $ 10,000 | $ 10,000 | |
Inventory Valuation Reserves, Ending Balance | $ 763,000 | $ 220,000 | |
Options and Warrants [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 3,203,553 | 3,710,335 | |
Minimum [Member] | |||
Property, Plant and Equipment, Useful Life | 2 years | ||
Maximum [Member] | |||
Property, Plant and Equipment, Useful Life | 7 years | ||
Milestone Education LLC [Member] | |||
Additional Interest In Subsidiaries Acquired During Period, Percentage. | 50.00% |
Note D - Notes Receivable (Deta
Note D - Notes Receivable (Details Textual) - USD ($) | Mar. 02, 2018 | Apr. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | Jun. 30, 2014 |
Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase | $ (250,000) | $ 250,000 | ||||
Milestone China [Member] | ||||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||
Financing Receivable, Net, Total | $ 2,800,000 | |||||
Equity Method Investment, Deferred Gain on Sale | $ 1,400,000 | |||||
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | ||||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||
Option to Repurchase, Period | 10 years | |||||
Price for Shares of Variable Interest Entity Interest Sold | $ 1,400,000 | |||||
Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase | 125,000 | |||||
Financing Receivable, Net, Total | 1,275,000 | |||||
Note Receivable, Quarterly Installment Amount | 125,000 | |||||
Option to Repurchase Variable Interest Entity Shares, Purchase Price | $ 1,400,000 | |||||
Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period | 2 years | |||||
Equity Method Investment, Deferred Gain on Sale | $ 1,400,000 | |||||
Return Obligation, Amount Repaid | $ 250,000 | |||||
Notes Receivable, Reversal Amount | $ 1,150,000 | |||||
Equity Method Investment, Reversal of Deferred Gain on Sale | 1,400,000 | |||||
Termination Agreement, Gain (Loss) on Transaction | $ 0 |
Note E - Inventories (Details T
Note E - Inventories (Details Textual) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Inventory Valuation Reserves, Ending Balance | $ 763,000 | $ 220,000 |
Slow Moving Medical Finished Goods [Member] | ||
Inventory Valuation Reserves, Ending Balance | 454,183 | |
Slow Moving Dental Finished Goods [Member] | ||
Inventory Valuation Reserves, Ending Balance | $ 309,196 |
Note E - Inventories - Summary
Note E - Inventories - Summary of Inventories (Details) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Component parts and other materials | $ 123,918 | $ 57,652 |
Total inventories | 1,921,051 | 3,379,209 |
Dental Segment [Member] | ||
Dental finished goods, net | 1,609,000 | 2,846,272 |
Medical Segment [Member] | ||
Dental finished goods, net | $ 188,133 | $ 475,285 |
Note F - Advances on Contracts
Note F - Advances on Contracts (Details Textual) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Advances on Inventory Purchases | $ 648,783 | $ 697,192 |
Note G - Consolidation of Var_2
Note G - Consolidation of Variable Interest Entity (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |
Sep. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Payments to Acquire Additional Interest in Subsidiaries | $ 8,020 | ||
Milestone Education LLC [Member] | |||
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage | 50.00% | ||
Percentage of Revenue from Services Performed to Variable Interest Entity | 84.00% | 84.00% | |
Additional Interest In Subsidiaries Acquired During Period, Percentage. | 50.00% | ||
Payments to Acquire Additional Interest in Subsidiaries | $ 8,020 |
Note H - Investment in and Tr_3
Note H - Investment in and Transactions with Unconsolidated Subsidiaries (Details Textual) | 1 Months Ended | 5 Months Ended | 12 Months Ended | |||
Apr. 30, 2018USD ($) | Jun. 30, 2017USD ($) | Jun. 30, 2014USD ($) | Nov. 30, 2018USD ($) | Dec. 31, 2018USD ($) | Dec. 31, 2017USD ($) | |
Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase | $ (250,000) | $ 250,000 | ||||
Income (Loss) from Equity Method Investments, Total | 329,700 | (120,510) | ||||
Milestone China [Member] | ||||||
Equity Method Investments | $ 1,000,000 | 0 | 0 | |||
Long-term Purchase Commitment, Minimum Quantity Required | 772 | |||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||
Financing Receivable, Net, Total | 2,800,000 | |||||
Equity Method Investment, Deferred Gain on Sale | $ 1,400,000 | |||||
Revenue from Related Parties | 900,000 | 2,071,000 | ||||
Contract with Customer, Liability, Total | 100,000 | 1,700,000 | ||||
Capitalized Contract Cost, Net, Total | 500,000 | 1,100,000 | ||||
Account Receivables, Related Party, Monthly Payment | $ 200,000 | |||||
Accounts Receivable, Related Party, Balloon Payment to be Paid | $ 1,425,000 | |||||
Proceeds from Collection of Finance Receivables | $ 900,000 | |||||
Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage | 40.00% | |||||
Income (Loss) from Equity Method Investments, Total | $ (329,700) | 120,510 | ||||
Cost-method Investments, Realized Losses | 3,380,388 | 3,147,470 | ||||
Inventory Adjustments, Total | 1,250,000 | |||||
Milestone China [Member] | Accounts Receivable from Related Parties [Member] | ||||||
Equity Method Investment, Deferred Intercompany Profit (Loss) | $ 421,800 | $ 751,500 | ||||
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | ||||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||
Option to Repurchase, Period | 10 years | |||||
Price for Shares of Variable Interest Entity Interest Sold | $ 1,400,000 | |||||
Proceeds from Sale of Variable Interest Entity Shares with Agreement to Repurchase | 125,000 | |||||
Financing Receivable, Net, Total | 1,275,000 | |||||
Note Receivable, Quarterly Installment Amount | 125,000 | |||||
Option to Repurchase Variable Interest Entity Shares, Purchase Price | $ 1,400,000 | |||||
Option to Repurchase Variable Entity Shares at Specified Purchase Price, Period | 2 years | |||||
Equity Method Investment, Deferred Gain on Sale | $ 1,400,000 | |||||
Variable Interest Entity Ownership Percentage Sold | 40.00% | |||||
Notes Receivable, Reversal Amount | $ 1,150,000 | |||||
Equity Method Investment, Reversal of Deferred Gain on Sale | 1,400,000 | |||||
Termination Agreement, Gain (Loss) on Transaction | 0 | |||||
Milestone China [Member] | Sale of Variable Interest Entity's Shares [Member] | Upon Exercise of Default Agreement [Member] | ||||||
Return Obligation, Amount | $ 250,000 |
Note H - Investment in Unconsol
Note H - Investment in Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Current liabilities | $ 17,696,033 | $ 18,468,937 |
Stockholders' deficit | (2,504,900) | (2,127,995) |
Total liabilities and stockholders’ deficit | 15,191,133 | 16,340,942 |
Net sales | 7,598,998 | 1,394,760 |
Cost of goods sold | 3,539,138 | 477,200 |
Gross profit | 4,059,860 | 917,560 |
Other expenses | (4,642,154) | (5,975,360) |
Net Losses | (582,294) | (5,057,800) |
Milestone China [Member] | ||
Current assets | 10,587,648 | 13,127,422 |
Non-current assets | 4,603,485 | 3,213,520 |
Total assets: | $ 15,191,133 | $ 16,340,942 |
Note I - Furniture, Fixtures _3
Note I - Furniture, Fixtures and Equipment (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Depreciation, Total | $ 66,604 | $ 62,474 |
Note I - Furniture, Fixtures _4
Note I - Furniture, Fixtures and Equipment - Summary of Furniture, Fixtures and Equipment (Details) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Furniture, fixtures and equipment, net | $ 82,557 | $ 141,760 |
Leasehold Improvements [Member] | ||
Furniture, fixtures and equipment | 24,734 | 24,734 |
Office Furniture and Equipment [Member] | ||
Furniture, fixtures and equipment | 134,948 | 134,947 |
Tools, Dies and Molds [Member] | ||
Furniture, fixtures and equipment | 7,200 | 7,200 |
Trade Show Displays [Member] | ||
Furniture, fixtures and equipment | 143,357 | 143,357 |
Computer and Software [Member] | ||
Furniture, fixtures and equipment | 278,766 | 270,904 |
Tooling Safety Wand [Member] | ||
Furniture, fixtures and equipment | 125,022 | 125,022 |
Tooling Equipment - STA and Wand [Member] | ||
Furniture, fixtures and equipment | 11,100 | 11,100 |
EPI and IA Instruments [Member] | ||
Furniture, fixtures and equipment | 82,362 | 82,363 |
STA Trials Instruments [Member] | ||
Furniture, fixtures and equipment | 63,752 | 63,752 |
Furniture and Fixtures [Member] | ||
Furniture, fixtures and equipment | 871,241 | 863,379 |
Less accumulated depreciation | (788,684) | (721,619) |
Furniture, fixtures and equipment, net | $ 82,557 | $ 141,760 |
Note J - Patents (Details Textu
Note J - Patents (Details Textual) | Jul. 13, 2017USD ($)shares | Jul. 13, 2017EUR (€)shares | Dec. 31, 2018USD ($)shares | Dec. 31, 2017USD ($) |
Amortization of Intangible Assets, Total | $ 814,681 | $ 510,676 | ||
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months | 53,000 | |||
Finite-Lived Intangible Assets, Amortization Expense, Year Two | 53,000 | |||
Finite-Lived Intangible Assets, Amortization Expense, Year Three | 53,000 | |||
Finite-Lived Intangible Assets, Amortization Expense, Year Four | 47,000 | |||
Finite-Lived Intangible Assets, Amortization Expense, Year Five | $ 33,000 | |||
Stock Issued During Period, Shares, Purchase of Assets | shares | 244,959 | |||
Stock Issued During Period, Value, Purchase of Assets | $ 286,601 | 2,486,000 | ||
Impairment of Intangible Assets, Finite-lived | 1,539,794 | |||
APAD Octrooi B.V. and APAD B.V. [Member] | ||||
Stock Issued During Period, Shares, Purchase of Assets | shares | 1,646,358 | 1,646,358 | ||
Stock Issued During Period, Value, Purchase of Assets | $ 2,486,000 | |||
Asset Purchase Agreement, Post-closing Adjustments, Percentage of Initial Shares, Maximum | 25.00% | 25.00% | ||
Asset Purchase Agreement, Post-closing Adjustments, Amount of Initial Shares, Maximum | € | € 250,000 | |||
Patents [Member] | ||||
Finite-Lived Intangible Asset, Useful Life | 3 years | 3 years | ||
Amortization of Intangible Assets, Total | $ 814,681 | $ 510,676 | ||
Finite-lived Intangible Assets Acquired | $ 2,639,000 | |||
Patents [Member] | Minimum [Member] | ||||
Finite-Lived Intangible Asset, Useful Life | 3 years | |||
Patents [Member] | Maximum [Member] | ||||
Finite-Lived Intangible Asset, Useful Life | 20 years |
Note J - Patents - Summary of P
Note J - Patents - Summary of Patents (Details) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Patents, cost | $ 4,017,510 | $ 4,017,510 |
Patents, impairment | (1,539,794) | |
Patents, accumulated amortization | (2,042,443) | (1,227,762) |
Patents, net | 435,273 | 2,789,748 |
Foundation Intellectual Property Patents [Member] | ||
Patents, cost | 1,377,863 | 1,377,863 |
Patents, impairment | ||
Patents, accumulated amortization | (942,590) | (787,821) |
Patents, net | 435,273 | 590,042 |
Epidural-Apad Patents [Member] | ||
Patents, cost | 2,639,647 | 2,639,647 |
Patents, impairment | (1,539,794) | |
Patents, accumulated amortization | (1,099,853) | (439,941) |
Patents, net | $ 2,199,706 |
Note K - Stockholders' Equity (
Note K - Stockholders' Equity (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | ||||
Feb. 28, 2019 | Jan. 31, 2017 | Dec. 31, 2016 | May 31, 2014 | Dec. 31, 2018 | Dec. 31, 2017 | |
Proceeds from Issuance of Private Placement | $ 250,000 | $ 10,000,000 | $ 150,836 | |||
Common Stock, Capital Shares Reserved for Future Issuance | 5,315,974 | 5,111,582 | ||||
Other Stock Options and Warrants [Member] | ||||||
Common Stock, Capital Shares Reserved for Future Issuance | 2,845,409 | 3,710,335 | ||||
Chief Executive Officer, Chief Financial Officer and Employees [Member] | ||||||
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance | 1,374,931 | 1,908,813 | ||||
Non-Employees [Member] | ||||||
Common Stock, Capital Shares Reserved for Future Issuance | 561,752 | 26,316 | ||||
Underwritten Public Offering [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 2,000,000 | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,592,775 | |||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 0.75 | |||||
Shares Issued, Price Per Share | $ 1.50 | |||||
Proceeds from Issuance of Common Stock | $ 3,000,000 | |||||
Class of Warrant or Right, Expiration Period | 3 years | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 2.55 | |||||
Over-Allotment Option [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 123,700 | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 92,775 | |||||
Shares Issued, Price Per Share | $ 1.499 | |||||
Proceeds from Issuance of Common Stock | $ 186,000 | |||||
Private Placement [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 2,000,000 | |||||
Shares Issued, Price Per Share | $ 1.50 | |||||
Proceeds from Issuance of Common Stock | $ 3,000,000 | |||||
Proceeds from Issuance of Convertible Preferred Stock | $ 7,000,000 | |||||
Private Placement [Member] | Series A Convertible Preferred Stock [Member] | ||||||
Stock Issued During Period, Shares, New Issues | 7,000 | |||||
Shares Issued, Price Per Share | $ 1,000 | |||||
Preferred Stock, Redemption Price Per Share | 2.545 | |||||
Private Placement [Member] | Series A Convertible Preferred Stock [Member] | Conversion Price if Common Stock Not Trade at 3.15 [Member] | ||||||
Preferred Stock, Redemption Price Per Share | $ 1.50 |
Note L - Stock Option Plans (De
Note L - Stock Option Plans (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Jun. 30, 2011 | Jul. 31, 2004 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0 | $ 1.73 | |||
Income from Non-employee Options | $ 10,720 | $ 9,384 | |||
Employee Stock Option [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,806,741 | ||||
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount | 398,301 | $ 636,058 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $ 263,974 | $ 603,979 | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 273 days | 3 years 14 days | |||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 1.82 | ||||
Stock Option Plan 2004 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 750,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date | 3 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date | 5 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0 | ||||
Stock Option Plan 2011 [Member] | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date | 3 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date | 5 years | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,000,000 | 4,000,000 |
Note L - Stock Option Plans - S
Note L - Stock Option Plans - Summary of Option Activity for Employees and Non-employees (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Number of options (in shares) | 224,999 | ||
Weighted average exercise price, outstanding (in dollars per share) | $ 2.53 | ||
Weighted average remaining contractual life, outstanding (Year) | 2 years 146 days | 5 years 116 days | |
Weighted average exercise price, granted (in dollars per share) | $ 0 | $ 1.73 | |
Number of options exercisable (in shares) | 1,317,632 | ||
Weighted average exercise price, exercisable (in dollars per share) | $ 1.79 | ||
Weighted average remaining contractual life, exercisable (Year) | 2 years 54 days | ||
Number of options (in shares) | 1,670,221 | 224,999 | |
Weighted average exercise price, outstanding (in dollars per share) | $ 1.71 | $ 2.53 | |
Employee Stock Option [Member] | |||
Number of options (in shares) | 1,985,335 | 1,511,995 | |
Weighted average exercise price, outstanding (in dollars per share) | $ 1.74 | $ 1.74 | |
Weighted average remaining contractual life, outstanding (Year) | 3 years 14 days | 2 years 354 days | |
Aggregate intrinsic value, outstanding | $ 25,160 | $ 102,605 | |
Number of options granted (in shares) | 1,806,741 | ||
Weighted average exercise price, granted (in dollars per share) | $ 1.82 | ||
Weighted average remaining contractual life, granted (Year) | 4 years 251 days | ||
Aggregate intrinsic value, granted | $ 25,610 | ||
Number of options exercised (in shares) | (83,333) | ||
Weighted average exercise price, exercised (in dollars per share) | $ 0.75 | ||
Number of options forfeited and expired (in shares) | (315,114) | (1,250,068) | |
Number of options exercisable (in shares) | 1,317,441 | ||
Weighted average exercise price, exercisable (in dollars per share) | $ 1.84 | ||
Weighted average remaining contractual life, exercisable (Year) | 2 years 167 days | ||
Aggregate intrinsic value, exercisable | $ 8,537 | ||
Forfeited or expired (in dollars per share) | $ 1.50 | ||
Number of options (in shares) | 1,985,335 | 1,511,995 | |
Weighted average exercise price, outstanding (in dollars per share) | $ 1.74 | $ 1.74 | |
Non-employee Options [Member] | |||
Number of options (in shares) | 224,999 | ||
Weighted average exercise price, outstanding (in dollars per share) | $ 2.53 | ||
Weighted average remaining contractual life, outstanding (Year) | 2 years 343 days | 4 years 116 days | |
Number of options granted (in shares) | 8,333 | ||
Weighted average exercise price, granted (in dollars per share) | $ 0.75 | ||
Weighted average remaining contractual life, granted (Year) | 4 years 120 days | ||
Number of options forfeited and expired (in shares) | (200,000) | ||
Number of options exercisable (in shares) | 27,777 | 23,067 | |
Weighted average exercise price, exercisable (in dollars per share) | $ 2.10 | $ 2.22 | |
Weighted average remaining contractual life, exercisable (Year) | 2 years 240 days | 4 years 138 days | |
Forfeited or expired (in dollars per share) | $ 2.55 | ||
Number of options (in shares) | 33,332 | 224,999 | |
Weighted average exercise price, outstanding (in dollars per share) | $ 1.87 | $ 2.53 |
Note L - Stock Option Plans - W
Note L - Stock Option Plans - Weighted Average Assumptions (Details) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Volatility | ||
Risk-free interest | ||
Expected Life (Year) | ||
Dividend yield | 0.00% | |
Forfeiture Rate | 6.00% | |
Minimum [Member] | ||
Volatility | 81.23% | |
Risk-free interest | 1.40% | |
Expected Life (Year) | 2 years | |
Maximum [Member] | ||
Volatility | 97.24% | |
Risk-free interest | 2.20% | |
Expected Life (Year) | 5 years |
Note M - Employment Contract _2
Note M - Employment Contract and Consulting Agreements (Details Textual) - USD ($) | Dec. 19, 2017 | Oct. 05, 2017 | Oct. 02, 2017 | Dec. 01, 2016 | Sep. 01, 2009 | Jul. 31, 2017 | Jun. 30, 2011 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0 | $ 1.73 | ||||||||
Stock Option Plan 2011 [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,000,000 | 4,000,000 | ||||||||
Employee Stock Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,806,741 | |||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 1.82 | |||||||||
Chief Executive Officer [Member] | ||||||||||
Chief Executive Officer, Employment Agreement Period | 1 year | 5 years | ||||||||
Chief Executive Officer, Automatic Extended Employment Agreement Period | 1 year | 1 year | ||||||||
Deferred Compensation Arrangement with Individual, Compensation Expense | $ 280,000 | $ 300,000 | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||
Minimum Shareholding Percentage in Company | 10.00% | |||||||||
Options Exercisable Period | 30 days | |||||||||
Employment Contracts, Payments for Health Insurance Coverage | $ 4,900 | |||||||||
Employment Contracts, Car Allowance | 7,200 | |||||||||
Employment Contracts, Pension Payment | $ 203,111 | |||||||||
Deferred Compensation Arrangement with Individual, Shares Issued | 1,055,135 | 886,866 | ||||||||
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued | $ 1,205,707 | $ 1,030,875 | ||||||||
Chief Executive Officer [Member] | Employee Stock Option [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||
Chief Executive Officer [Member] | Maximum [Member] | ||||||||||
Accrued Bonuses, Current | $ 400,000 | |||||||||
Former President and Chief Executive Officer [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||
Employment Agreement Term | 3 years | |||||||||
Employment Agreement, Base Compensation | $ 300,000 | |||||||||
Employment Agreement, Maximum Bonuses | $ 400,000 | |||||||||
Former President and Chief Executive Officer [Member] | Non-qualified Stock Options [Member] | Stock Option Plan 2011 [Member] | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 921,942 | |||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 2 | |||||||||
Former CEO [Member] | ||||||||||
Employee Resignation Assertion, Health and Disability Insurance for One Year | $ 30,000 | |||||||||
Employee Resignation Assertion, Car Allowance for One Year | $ 1,200 | |||||||||
Employee Resignation Assertion, Gross Settlement | $ 175,000 | |||||||||
Previous President and Chief Executive Officer [Member] | ||||||||||
Employment Agreement Term | 10 years | |||||||||
Employment Agreement, Base Compensation | $ 300,000 | |||||||||
Employment Agreement, Base Compensation, Cash | 100,000 | |||||||||
Employment Agreement, Base Compensation, Common Stock Value | $ 200,000 | |||||||||
Consulting Agreement, Term | 10 years | |||||||||
Consulting Agreement, Annual Payment | $ 100,000 | |||||||||
Interim Chief Executive Officer [Member] | ||||||||||
Employment Agreement, Base Compensation | $ 200,000 | |||||||||
Employment Agreement, Base Compensation, Common Stock Value | $ 100,000 | |||||||||
Employment Agreement, One-Time Bonus | $ 25,000 |
Note N - Income Taxes (Details
Note N - Income Taxes (Details Textual) - USD ($) | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Operating Loss Carryforwards, Valuation Allowance, Total | $ 0 | $ 0 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 34.00% | |
Deferred Tax Assets Gross, Increase (Decrease) Due to New Tax Cuts and Jobs Act 2017 | $ (8,677,000) | ||
Percentage of Valuation Allowance | 100.00% | ||
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | $ 24,000 | 19,000 | |
Unrecognized Tax Benefits, Ending Balance | 0 | 0 | |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total | 0 | 0 | |
Tax Year 2015 [Member] | |||
Open Tax Year | 2015 | ||
Tax Year 2016 [Member] | |||
Open Tax Year | 2016 | ||
Domestic Tax Authority [Member] | |||
Operating Loss Carryforwards, Total | 65,300,000 | 60,000,000 | |
State and Local Jurisdiction [Member] | |||
Operating Loss Carryforwards, Total | $ 30,800,000 | $ 26,000,000 |
Note N - Income Taxes - Deferre
Note N - Income Taxes - Deferred Tax Assets (Details) - USD ($) | Dec. 31, 2018 | Dec. 31, 2017 |
Allowance for doubtful accounts | $ 3,000 | $ 3,000 |
Warranty reserve | 29,000 | 20,000 |
Impaired Assets | 435,000 | 5,000 |
Inventory Reserve | 551,000 | |
Capital Gains | 45,000 | |
Deferred officers' compensation | 715,000 | 636,000 |
Depreciation and Amortization | 345,000 | 181,000 |
Deferred revenue | 478,000 | |
Net operating loss carryforward | 16,500,000 | 15,116,000 |
Subtotal | 18,578,000 | 16,484,000 |
Valuation allowance | (18,578,000) | (16,484,000) |
Non-current deferred tax asset |
Note N - Income Taxes - Reconci
Note N - Income Taxes - Reconciliation of the Statutory Tax Rates (Details) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Statutory rate | 21.00% | 34.00% |
State income tax-all states | 7.00% | 6.00% |
Non-deductible Stock based compensation | 0.00% | 0.00% |
Deferred provision for effect of change in Federal rate | 0.00% | 164.00% |
28.00% | 204.00% | |
Valuation allowance | (28.00%) | (204.00%) |
Effective tax rate | 0.00% | 0.00% |
Note O - Segment and Geograph_3
Note O - Segment and Geographic Data (Details Textual) | 12 Months Ended |
Dec. 31, 2018 | |
Number of Reportable Segments | 2 |
Note O - Segment and Geograph_4
Note O - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Product sales, net | $ 9,622,076 | $ 11,281,886 |
Operating Income (Loss) | (7,999,335) | (5,234,318) |
Depreciation and Amortization | 881,285 | 573,150 |
Income (loss) before taxes and equity in earnings of affiliates | (7,999,120) | (5,229,950) |
Assets | 6,400,968 | 15,628,787 |
Corporate, Non-Segment [Member] | ||
Operating Income (Loss) | (6,761,282) | (5,972,743) |
Depreciation and Amortization | 840,319 | 528,895 |
Income (loss) before taxes and equity in earnings of affiliates | (6,658,152) | (5,975,035) |
Assets | 902,816 | 4,718,130 |
Dental Segment [Member] | ||
Product sales, net | 9,502,276 | 11,279,886 |
Dental Segment [Member] | Operating Segments [Member] | ||
Product sales, net | 9,502,276 | 11,279,886 |
Operating Income (Loss) | 1,373,178 | 3,127,570 |
Depreciation and Amortization | 16,474 | 17,305 |
Income (loss) before taxes and equity in earnings of affiliates | 1,363,662 | 3,136,167 |
Assets | 5,169,944 | 10,255,144 |
Medical Segment [Member] | ||
Product sales, net | 119,800 | 2,000 |
Medical Segment [Member] | Operating Segments [Member] | ||
Product sales, net | 119,800 | 2,000 |
Operating Income (Loss) | (2,611,231) | (2,389,145) |
Depreciation and Amortization | 24,492 | 26,950 |
Income (loss) before taxes and equity in earnings of affiliates | (2,704,630) | (2,391,082) |
Assets | $ 328,208 | $ 655,513 |
Note O - Segment and Geograph_5
Note O - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Product sales, net | $ 9,622,076 | $ 11,281,886 |
Domestic [Member] | ||
Product sales, net | 4,831,206 | 5,339,709 |
Domestic [Member] | Devices [Member] | ||
Product sales, net | 523,875 | 914,495 |
Domestic [Member] | Handpieces [Member] | ||
Product sales, net | 4,211,243 | 4,346,664 |
Domestic [Member] | Other Products [Member] | ||
Product sales, net | 96,088 | 78,550 |
Rest of World [Member] | ||
Product sales, net | 3,890,870 | 3,871,177 |
Rest of World [Member] | Devices [Member] | ||
Product sales, net | 1,373,844 | 1,427,016 |
Rest of World [Member] | Handpieces [Member] | ||
Product sales, net | 2,450,739 | 2,327,622 |
Rest of World [Member] | Other Products [Member] | ||
Product sales, net | 66,287 | 116,539 |
CHINA | ||
Product sales, net | 900,000 | 2,071,000 |
CHINA | Devices [Member] | ||
Product sales, net | 109,374 | 643,600 |
CHINA | Handpieces [Member] | ||
Product sales, net | 790,626 | 1,425,600 |
CHINA | Other Products [Member] | ||
Product sales, net | 1,800 | |
Dental Segment [Member] | ||
Product sales, net | 9,502,276 | 11,279,886 |
Dental Segment [Member] | Domestic [Member] | ||
Product sales, net | 4,798,706 | 5,339,709 |
Dental Segment [Member] | Domestic [Member] | Devices [Member] | ||
Product sales, net | 491,375 | 914,495 |
Dental Segment [Member] | Domestic [Member] | Handpieces [Member] | ||
Product sales, net | 4,211,243 | 4,346,664 |
Dental Segment [Member] | Domestic [Member] | Other Products [Member] | ||
Product sales, net | 96,088 | 78,550 |
Dental Segment [Member] | Rest of World [Member] | ||
Product sales, net | 3,803,570 | 3,869,177 |
Dental Segment [Member] | Rest of World [Member] | Devices [Member] | ||
Product sales, net | 1,292,844 | 1,427,016 |
Dental Segment [Member] | Rest of World [Member] | Handpieces [Member] | ||
Product sales, net | 2,444,639 | 2,325,622 |
Dental Segment [Member] | Rest of World [Member] | Other Products [Member] | ||
Product sales, net | 66,087 | 116,539 |
Dental Segment [Member] | CHINA | ||
Product sales, net | 900,000 | 2,071,000 |
Dental Segment [Member] | CHINA | Devices [Member] | ||
Product sales, net | 109,374 | 643,600 |
Dental Segment [Member] | CHINA | Handpieces [Member] | ||
Product sales, net | 790,626 | 1,425,600 |
Dental Segment [Member] | CHINA | Other Products [Member] | ||
Product sales, net | 1,800 | |
Medical Segment [Member] | ||
Product sales, net | 119,800 | 2,000 |
Medical Segment [Member] | Domestic [Member] | ||
Product sales, net | 32,500 | |
Medical Segment [Member] | Domestic [Member] | Devices [Member] | ||
Product sales, net | 32,500 | |
Medical Segment [Member] | Domestic [Member] | Handpieces [Member] | ||
Product sales, net | ||
Medical Segment [Member] | Domestic [Member] | Other Products [Member] | ||
Product sales, net | ||
Medical Segment [Member] | Rest of World [Member] | ||
Product sales, net | 87,300 | 2,000 |
Medical Segment [Member] | Rest of World [Member] | Devices [Member] | ||
Product sales, net | 81,000 | |
Medical Segment [Member] | Rest of World [Member] | Handpieces [Member] | ||
Product sales, net | 6,100 | 2,000 |
Medical Segment [Member] | Rest of World [Member] | Other Products [Member] | ||
Product sales, net | 200 | |
Medical Segment [Member] | CHINA | ||
Product sales, net | ||
Medical Segment [Member] | CHINA | Devices [Member] | ||
Product sales, net | ||
Medical Segment [Member] | CHINA | Handpieces [Member] | ||
Product sales, net | ||
Medical Segment [Member] | CHINA | Other Products [Member] | ||
Product sales, net |
Note P - Concentration (Details
Note P - Concentration (Details Textual) | 3 Months Ended | 12 Months Ended | |
Sep. 30, 2017 | Dec. 31, 2018USD ($) | Dec. 31, 2017USD ($) | |
Accounts Receivable, Gross | $ 2,078,457 | ||
Allowance for Doubtful Accounts Receivable, Ending Balance | 10,000 | $ 10,000 | |
Milestone China [Member] | |||
Accounts Receivable, Gross | 1,917,990 | ||
Allowance for Doubtful Accounts Receivable, Ending Balance | 1,817,990 | ||
Provision for Doubtful Accounts | $ 1,250,928 | ||
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | |||
Number of Customers | 2 | 2 | |
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | |||
Concentration Risk, Percentage | 53.00% | 70.00% | |
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 43.00% | 51.00% | |
Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | |||
Concentration Risk, Percentage | 10.00% | 19.00% | |
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | |||
Concentration Risk, Percentage | 63.00% | ||
Accounts Receivable, Gross | $ 82 | ||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member] | |||
Concentration Risk, Percentage | 49.00% | ||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | |||
Concentration Risk, Percentage | 33.00% | ||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member] | |||
Concentration Risk, Percentage | 78.00% | ||
Accounts Receivable, Gross | $ 2,555,000 |
Note Q - Related Party Transa_2
Note Q - Related Party Transactions (Details Textual) | 1 Months Ended | 5 Months Ended | 12 Months Ended | 24 Months Ended | ||||
Feb. 28, 2019USD ($)$ / sharesshares | Jan. 31, 2017 | Aug. 31, 2016 | Jun. 30, 2014USD ($) | Nov. 30, 2018USD ($) | Dec. 31, 2018USD ($) | Dec. 31, 2017USD ($) | Dec. 31, 2018USD ($) | |
Stock Issued During Period, Value, Issued for Services | $ 289,750 | $ 548,511 | ||||||
Director of Clinical Affairs [Member] | ||||||||
Royalty Expense | 465,000 | 554,000 | ||||||
Professional Fees | 186,000 | 275,000 | ||||||
Accounts Payable, Related Parties | 364,000 | 162,000 | $ 364,000 | |||||
Milestone China [Member] | ||||||||
Revenue from Related Parties | 900,000 | 2,071,000 | ||||||
Capitalized Contract Cost, Net, Total | 500,000 | 1,100,000 | 500,000 | |||||
Financing Receivable, Net, Total | 2,800,000 | 2,800,000 | ||||||
Account Receivables, Related Party, Monthly Payment | $ 200,000 | |||||||
Accounts Receivable, Related Party, Balloon Payment to be Paid | $ 1,425,000 | |||||||
Proceeds from Collection of Finance Receivables | 900,000 | |||||||
Inventory Adjustments, Total | 1,250,000 | 1,250,000 | ||||||
Equity Method Investments | $ 1,000,000 | 0 | 0 | 0 | ||||
Long-term Purchase Commitment, Minimum Quantity Required | 772 | |||||||
Equity Method Investment, Ownership Percentage | 40.00% | |||||||
United Systems [Member] | ||||||||
Capitalized Contract Cost, Net, Total | 686,365 | 686,365 | ||||||
Wand Dental Inc [Member] | ||||||||
Deferred Revenue, Current | 342,540 | 342,540 | ||||||
Manufacturing Agreement for Handpieces [Member] | ||||||||
Related Party Transaction, Purchases from Related Party | 1,200,000 | 2,100,000 | ||||||
Due to Related Parties, Total | 1,300,000 | 1,000,000 | 1,300,000 | |||||
Consulting Services [Member] | ||||||||
Consulting Services Agreement, Term | 3 years | |||||||
Related Party Transaction, Expenses from Transactions with Related Party | 100,000 | $ 100,000 | ||||||
Consulting Services [Member] | United Systems [Member] | Subsequent Event [Member] | ||||||||
Stock Issued During Period, Shares, Issued for Services | shares | 285,714 | |||||||
Shares Issued, Price Per Share | $ / shares | $ 0.35 | |||||||
Stock Issued During Period, Value, Issued for Services | $ 100,000 | |||||||
Consulting Services [Member] | Innovest S.p.A. [Member] | ||||||||
Related Party Transaction, Expenses from Transactions with Related Party | $ 80,000 | |||||||
Distributor Agreement to Milestone China [Member] | United Systems [Member] | ||||||||
Revenue from Related Parties | 750,000 | |||||||
Consultant [Member] | Innovest S.p.A. [Member] | ||||||||
Consulting Services Agreement, Term | 1 year | |||||||
Related Party Transaction, Expenses from Transactions with Related Party | $ 80,000 |
Note R - Commitments and Other
Note R - Commitments and Other (Details Textual) | Jan. 01, 2005 | Jan. 31, 2018 | Dec. 31, 2018USD ($)ft² | Dec. 31, 2017USD ($) |
Advances on Inventory Purchases | $ 648,783 | $ 697,192 | ||
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology | 2.50% | |||
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology | 5.00% | |||
Area of Office Space | ft² | 7,625 | |||
Operating Leases, Rent Expense, Minimum Rentals | $ 12,522 | |||
Director of Clinical Affairs [Member] | ||||
Royalty Expense | 465,000 | 554,000 | ||
Professional Fees | 186,000 | 275,000 | ||
Accounts Payable, Related Parties | 364,000 | 162,000 | ||
Director Clinical Affair [Member] | ||||
Professional Fees | 186,000 | 275,000 | ||
Accounts Payable, Related Parties | 364,000 | $ 162,000 | ||
Purchase Commitment for Devices [Member] | ||||
Purchase Commitment Number Of Units | 2,000 | |||
Purchase Commitment, Remaining Minimum Amount Committed | 873,400 | |||
Advances on Inventory Purchases | 596,724 | |||
Purchase Obligation, Total | $ 259,801 |
Note T - Subsequent Events (Det
Note T - Subsequent Events (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Mar. 31, 2019 | Feb. 28, 2019 | May 31, 2014 | Dec. 31, 2018 | Dec. 31, 2017 | |
Proceeds from Stock Options Exercised | $ 62,500 | ||||
Proceeds from Issuance of Private Placement | $ 250,000 | $ 10,000,000 | $ 150,836 | ||
Private Placement [Member] | |||||
Stock Issued During Period, Shares, New Issues | 2,000,000 | ||||
Subsequent Event [Member] | Warrants, Public Offering [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,428,000 | ||||
Warrants and Rights Outstanding, Term | 5 years | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.50 | ||||
Subsequent Event [Member] | Warrants, Private Offering [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 178,594 | ||||
Subsequent Event [Member] | Public Offering [Member] | |||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,000,000 | ||||
Stock Issued During Period, Shares, New Issues | 5,715,000 | ||||
Proceeds from Stock Options Exercised | $ 198,000 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 567,400 | ||||
Subsequent Event [Member] | Private Placement [Member] | |||||
Stock Issued During Period, Shares, New Issues | 714,286 |